A single low dose of dendritic cells modified with lentivirus containing a truncated neu gene can effectively suppress neu-overexpressing tumors.
BACKGROUND
Several types of viral-transduced HER2/neu-modified dendritic cells (DC(HER2/neu)) have been used for preventing and/or treating HER2/neu-overexpressing tumors. However, to date, lentivirus has not been used to generate HER2/neu-modified DCs.


METHODS
In the present study, we used recombinant lentivirus containing a truncated neu gene (rLVneu) to transduce murine bone marrow-derived dendritic cells and investigated their preventive and therapeutic effects on HER2/neu-overexpressing tumors.


RESULTS
The data obtained show that a single low dose of lentiviral-transduced DC(HER2/neu) could significantly elevate serum anti-neu antibody level, stimulate the proliferation of CD4 and CD8 T lymphocytes and interferon-gamma secretion, induce a long lasting preventive effect against HER2/neu-overexpressing tumors and significantly suppress the growth of established HER2/neu-overexpressing tumors.


CONCLUSIONS
The present study demonstrates that a single low dose of DCs modified with rLV containing a truncated neu oncogene can achieve a strong and long lasting effect on neu-overexpressing tumors, suggesting the possible clinical application of this strategy.
Li
Gong-Bo
GB
Institute of Human Reproduction and Stem Cell Engineering, Central South University, National Engineering and Research Center of Human Stem Cell, Changsha, China.
Lu
Guang-Xiu
GX
D000818:Animals; D000912:Antibodies, Neoplasm / Q000097:blood; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000276:immunology*; D018572:Disease-Free Survival; D007371:Interferon-gamma / Q000378:metabolism; D016086:Lentivirus / Q000235:genetics*; D051379:Mice; D008810:Mice, Inbred C57BL; D050505:Mutant Proteins / Q000235:genetics*; D009369:Neoplasms / Q000097:blood / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D010641:Phenotype; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D013997:Time Factors; D014161:Transduction, Genetic; D014611:Vaccination
D000912:Antibodies, Neoplasm; D019496:Cancer Vaccines; D007371:Interferon-gamma; D050505:Mutant Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases